WO2008128352A1 - Procédés et compositions pour amplifier un signal - Google Patents
Procédés et compositions pour amplifier un signal Download PDFInfo
- Publication number
- WO2008128352A1 WO2008128352A1 PCT/CA2008/000750 CA2008000750W WO2008128352A1 WO 2008128352 A1 WO2008128352 A1 WO 2008128352A1 CA 2008000750 W CA2008000750 W CA 2008000750W WO 2008128352 A1 WO2008128352 A1 WO 2008128352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- binding agent
- analyte
- agent
- protein
- binding
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- 230000003321 amplification Effects 0.000 title abstract description 15
- 238000003199 nucleic acid amplification method Methods 0.000 title abstract description 15
- 239000000203 mixture Substances 0.000 title abstract description 6
- 239000012491 analyte Substances 0.000 claims abstract description 48
- 230000003287 optical effect Effects 0.000 claims abstract description 16
- 239000011230 binding agent Substances 0.000 claims description 95
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 238000002372 labelling Methods 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 230000003197 catalytic effect Effects 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 19
- 230000001376 precipitating effect Effects 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 229940088598 enzyme Drugs 0.000 claims description 11
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 8
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 7
- 102100032752 C-reactive protein Human genes 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 6
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 claims description 6
- 238000002835 absorbance Methods 0.000 claims description 6
- 229940100601 interleukin-6 Drugs 0.000 claims description 6
- 238000004020 luminiscence type Methods 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 5
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 5
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 5
- 108090001008 Avidin Proteins 0.000 claims description 5
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 5
- 108090000371 Esterases Proteins 0.000 claims description 5
- 108010015776 Glucose oxidase Proteins 0.000 claims description 5
- 239000004366 Glucose oxidase Substances 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 238000001069 Raman spectroscopy Methods 0.000 claims description 5
- 101710120037 Toxin CcdB Proteins 0.000 claims description 5
- 108010046334 Urease Proteins 0.000 claims description 5
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 5
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 5
- 102000006635 beta-lactamase Human genes 0.000 claims description 5
- 229940116332 glucose oxidase Drugs 0.000 claims description 5
- 235000019420 glucose oxidase Nutrition 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108010090804 Streptavidin Proteins 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 claims description 3
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 claims description 3
- MUGYJXWDGQOBET-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;4-(2-aminoethyl)phenol Chemical compound NCCC1=CC=C(O)C=C1.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 MUGYJXWDGQOBET-UFLZEWODSA-N 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- 108010075254 C-Peptide Proteins 0.000 claims description 3
- 101800000115 Copeptin Proteins 0.000 claims description 3
- 102000004878 Gelsolin Human genes 0.000 claims description 3
- 108090001064 Gelsolin Proteins 0.000 claims description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 3
- 102000003992 Peroxidases Human genes 0.000 claims description 3
- 230000003208 anti-thyroid effect Effects 0.000 claims description 3
- 229940043671 antithyroid preparations Drugs 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 3
- 108091005995 glycated hemoglobin Proteins 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 229960003732 tyramine Drugs 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 210000002845 virion Anatomy 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 239000000523 sample Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 11
- 230000003993 interaction Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102400000060 Copeptin Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WFZFMHDDZRBTFH-CZEFNJPISA-N 2-[(e)-2-(5-carbamimidoyl-1-benzofuran-2-yl)ethenyl]-1-benzofuran-5-carboximidamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)C1=CC=C2OC(/C=C/C=3OC4=CC=C(C=C4C=3)C(=N)N)=CC2=C1 WFZFMHDDZRBTFH-CZEFNJPISA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000709711 Coxsackievirus B5 Species 0.000 description 1
- 241001278349 Coxsackievirus B6 Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- -1 DNA or RNA Chemical class 0.000 description 1
- 241000244160 Echinococcus Species 0.000 description 1
- 241000709638 Echovirus E6 Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000589928 Leptospira biflexa Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025654 Malignant melanoma of sites other than skin Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 102100036836 Natriuretic peptides B Human genes 0.000 description 1
- 101710187802 Natriuretic peptides B Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004082 amperometric method Methods 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical class Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000979 dip-pen nanolithography Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000813 microcontact printing Methods 0.000 description 1
- 238000001393 microlithography Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
Definitions
- the invention relates to the fields of analyte detection and signal amplification.
- Detection technologies are often limited by their inability to detect analytes that may be present in the sample at low concentrations.
- Diffraction-based sensing provides a simple and sensitive method for the detection of biomolecular interactions. Unlike other technologies, grating-based methods do not require the use of fluorescent labels, and the detection beam never passes through the sample.
- diffraction-based technologies are limited by their ability to detect analytes present at low concentrations in a given sample. There is a need in the existing art for new methods of detecting analytes at low concentrations.
- the invention features methods, compositions, and kits for detecting analytes at low concentrations.
- the invention is particularly useful for detecting the presence of an analyte in a biological sample at low (e.g., femtomolar) concentrations.
- the invention features a method of detecting an analyte in a sample, wherein the method includes contacting a sample with a device having an immobilized binding agent capable of binding to an analyte to form a first complex containing the analyte bound to the immobilized binding agent; contacting the first complex with a first catalytic binding agent that binds to the analyte to form a second complex containing the immobilized binding agent, the analyte, and the first catalytic binding agent; contacting the second complex with a labeling agent, wherein the first catalytic binding agent activates the labeling agent, which then binds to the second complex or the device adjacent to the second complex; introducing into the device a second binding agent that binds to the labeling agent and amplifies a signal associated with the analyte; and detecting the signal.
- the analyte, first and second binding agents, and labeling agent of the method may be added to the immobilized binding agent on the surface of the device sequentially or as a homogenous mixture.
- the signal may be detected by measuring, e.g., optical diffraction, absorbance, fluorescence, Raman scattering, phosphorescence, luminescence, radioactivity, or surface plasmon resonance (SPR).
- the immobilized binding agent of the invention may be protein (e.g., avidin, streptavidin, Protein G, or an antibody) or nucleic acid.
- the immobilized binding agent may be disposed onto the surface of the device in a pattern capable of optical diffraction.
- the first catalytic binding agent and second binding agent may include protein (e.g., an antibody or an enzyme) or a nucleic acid.
- the enzyme may be horseradish peroxidase (HRP), alkaline phosphatase, acid phosphatase, glucose oxidase, beta-galactosidase, beta-lactamase, esterase, or urease.
- the labeling agent of the invention may be activated to react with an amino acid side chain (e.g., tyrosine) or a nucleic acid.
- Exemplary labeling agents include tyramide-dinitrophenyl, biotin tyramine, p-hydroxyphenylpropionyl-biocytin, fluorescein-tyramine, tyramide gold, tyramide polystyrene, tyramide protein devoid of tyrosine, and tyramide nanoparticles.
- the second binding agent may be a catalytic binding agent.
- the catalytic second binding agent may be contacted with a precipitating substrate. Contacting the second binding agent with the precipitating substrate amplifies the signal produced upon analyte binding to the surface of the device.
- Exemplary precipitating substrates include tetramethylbenzidene, 2,2-azino-di(3- ethylbenzthiazoline) sulfonic acid (ABTS), p-nitrophenyl phosphate (pNPP), 5- bromo-4-choro-3'-indolylphosphate (BCIP), diaminobenzidine (DAB), and orthophenylenediamine (OPD).
- ABTS 2,2-azino-di(3- ethylbenzthiazoline) sulfonic acid
- pNPP p-nitrophenyl phosphate
- BCIP 5- bromo-4-choro-3'-indolylphosphate
- DAB diaminobenzidine
- OPD orthophenylenediamine
- the second binding agent and labeling agent may be the same molecule.
- the labeling agent may be conjugated (e.g., via a covalent bond) to the second binding agent.
- the analyte of the invention is, e.g., DNA, RNA, proteins, hormones, lipids, virions, or cells.
- exemplary analytes include C-peptide, glycated hemoglobin, a lipoprotein, low-density lipoprotein (LDL), high-density lipoprotein (HDL), a cytokine, interleukin-6 (IL-6), thyroid- stimulating protein (TSH), anti-thyroid peroxidase (TPO) antibody, a hormone, C-reactive protein (CRP), gelsolin, and copeptin.
- the sample containing the analyte may be serum, plasma, crude cell lysates, or urine.
- Figure 1 shows the TMB response when different concentrations of NTproBNP are used in the assay.
- Rl data was collected from replicate 1 ;
- R2 data was collected from replicate 2.
- A A full-scale response curve is shown.
- B An expanded scale of part (A) is shown, illustrating the distinct rates between different concentrations.
- Figure 2 shows raw sensor data from all four concentrations of NTproBNP assayed, where (A) is 10 pg/ml, (B) is 1 pg/ml, (C) is 0.1 pg/ml, and (D) is 0 pg/ml.
- the invention provides methods, compositions, and kits for detecting analytes in a sample, typically present at low concentrations, e.g., femtomolar.
- the methods of the invention can be used to assess the presence or amounts of various biomarkers in a sample from a subject to facilitate diagnoses of disease and clinical assessments.
- the methods of the invention include contacting a sample with a device having an immobilized binding agent.
- the immobilized binding agent binds to an analyte present in the sample, forming a complex on the surface of the device.
- the complex bound to the device is contacted with a first catalytic binding agent that binds to the analyte.
- the complex thus formed on the surface of the device is contacted with a labeling agent.
- the first catalytic binding agent of the complex activates the labeling agent, which binds to the complex or adjacent to the complex.
- the device is also contacted with a second binding agent that binds to the labeling agent.
- the second binding agent can amplify a signal associated with an analyte.
- the signal may be detected using detection methods known to those skilled in the art. e.g., optical diffraction, absorbance, fluorescence, Raman scattering, phosphorescence, luminescence, radioactivity, or surface plasmon resonance.
- analytes include biomarkers and biomolecules, e.g., hormones, metabolites, DNA, RNA, microRNA, polynucleotides and their analogs, proteins, lipids, toxins, or drugs, as well as larger assemblies, such as virions or cells.
- biomarkers and biomolecules e.g., hormones, metabolites, DNA, RNA, microRNA, polynucleotides and their analogs, proteins, lipids, toxins, or drugs, as well as larger assemblies, such as virions or cells.
- Biomarkers including, e.g., C-peptide, glycated hemoglobin, a lipoprotein, low- density lipoprotein (LDL), high-density lipoprotein (HDL), a cytokine, interleukin-6 (IL-6), thyroid- stimulating protein (TSH), anti-thyroid peroxidase (TPO) antibodies, a hormone, C-reactive protein (CRP), gelsolin, and copeptin, may be detected by methods of the invention.
- the analytes may be present in a biological sample, e.g.. serum, plasma, crude cell lysates, or urine.
- concentrations of analytes may be detected and measured by the methods described herein.
- Analytes present at concentrations less than, e.g., 100 milligrams/milliliter, 10 milligrams/milliliter, 1 milligram/milliliter, 100 micrograms/milliliter, 10 micrograms/milliliter. 1 microgram/milliliter, 100 nanograms/milliliter, 10 nanograms/milliliter. 1 nanogram/milliliter, 100 picograms/milliliter, 10 picograms/milliliter, 1 picogram/milliliter, 100 femtograms/milliliter, or 10 femtograms/milliliter, may be detected and measured.
- the device of the invention contains immobilized binding agents at its surface.
- the immobilized binding agent may include any substance capable of binding an analyte, such as a protein (e.g., an antibody or fragment thereof, avidin, streptavidin, Protein G, or Protein A) or a polynucleotide.
- the polynucleotide may possess sequence specificity for the analyte or may be an aptamer.
- Other binding agents include, e.g., charged polymers, hydrophobic polymers, and carbohydrates.
- the binding agent immobilized in the device will ultimately depend on the analyte being assayed. Analytes may bind covalently or non-covalently to the immobilized binding agent.
- the immobilized binding agents may be immobilized in a device by known methods, such as a biotin-avidin or biotin- streptavidin interaction, a Protein G interaction, a GAM-Fc interaction, an amide bond, or through any other covalent or non-covalent interaction.
- the method may be scaled to detect or measure two. three, four, or more analytes in a sample simultaneously by using devices having two, three, four, or more immobilized binding agents.
- immobilized binding agents used in the devices of the invention may be agents that are, e.g., magnetic, positively charged, negatively charged, polarized, or capable of forming temporary dipoles, so that the immobilized binding agent can bind analytes in a sample by non-covalent means.
- the first catalytic binding agent of the invention may be, e.g., a protein or nucleic acid.
- the first catalytic binding agent is a protein, wherein the protein is an antibody conjugated to an enzyme.
- the enzyme may be horseradish peroxidase (HRP), alkaline phosphatase, acid phosphatase, glucose oxidase, beta- galactosidase, beta-lactamase, esterase, or urease.
- the second binding agent may be, e.g., a protein or nucleic acid.
- the second binding agent may also be catalytic.
- the second binding agent may be a protein, e.g., an antibody conjugated to an enzyme such as HRP, alkaline phosphatase, acid phosphatase, glucose oxidase, beta- galactosidase, beta- lactamase, esterase, or urease.
- an enzyme such as HRP, alkaline phosphatase, acid phosphatase, glucose oxidase, beta- galactosidase, beta- lactamase, esterase, or urease.
- a catalytic binding agent may be intrinsically catalytic or may be catalytic upon conjugation to a catalyst.
- exemplary catalysts include, e.g., enzymes, ribozymes, and transition metals. Other catalysts are known to those skilled in the art.
- Amplification of a signal produced upon analyte binding may be achieved by activating a labeling agent that binds to the complex or that binds adjacent to the complex on the surface of the device.
- the labeling agent may be, e.g., tyramide- dinitrophenyl, biotin tyramine, p-hydroxyphenylpropionyl-biocytin, fluorescein- tyramine, tyramide gold, tyramide polystyrene, tyramide protein devoid of tyrosine, or tyramide nanoparticles.
- the labeling agent may be activated to react with the complex, or any component thereof, or the surface of the device adjacent to the complex.
- the labeling agent may, for example, react with tyrosine or another amino acid side chain.
- the labeling agent may also react with a nucleic acid, e.g., DNA or RNA, the analyte, the immobilized binding agent, or the material to which the immobilized binding agent is bound.
- amplification of the signal produced upon analyte binding may be achieved by adding a precipitating substrate.
- the precipitating substrate may be selected from tetramethylbenzidene (TMB), 2,2- azino-di(3-ethylbenzthiazoline) sulfonic acid (ABTS), p-nitrophenyl phosphate (pNPP), 5-bromo-4-choro-3 ' -indolylphosphate (BCIP), diaminobenzidine (DAB), and orthophenylenediamine (OPD).
- TMB tetramethylbenzidene
- ABTS 2,2- azino-di(3-ethylbenzthiazoline) sulfonic acid
- pNPP p-nitrophenyl phosphate
- BCIP 5-bromo-4-choro-3 ' -indolylphosphate
- DAB diaminobenzidine
- OPD orthophenylenediamine
- the second binding agent may amplify the signal in the absence of a precipitating substrate.
- Signal amplification by addition of the second binding agent may be the result of, e.g., a gold or polystyrene nanoparticle connected to the second binding agent, fluorophores connected to the second binding agent, or a radioactive-label connected to the second binding agent.
- the second binding agent is connected to any moiety that may increase optical diffraction.
- the steps of the method can be repeated several times to provide multiple catalytic binding agents for each analyte bound to the surface of the sensor, thus amplifying the detection signal by one, two, or three orders of magnitude.
- Other labeling agents and precipitating substrates that would catalyze the deposition of large (e.g., diffraction-enhancing) moieties onto the surface of the device and enhance the binding signal may also be used.
- the synergistic effect of using a labeling agent and/or a precipitating substrate allows for significant enhancement in the sensitivity of the method used to detect the signal produced upon analyte binding.
- the signal produced upon analyte binding may be detected or measured using any technique known in the art, including, e.g., optical diffraction, absorbance, fluorescence, Raman scattering, phosphorescence, luminescence, radioactivity, or surface plasmon resonance. Exemplary techniques for detection are listed in, e.g., U.S. Patent No. 6.991,938, hereby incorporated by reference.
- Diffraction-based assays can involve immobilizing a binding agent, e.g., a protein or nucleic acid, in a distinct pattern on the surface of a device.
- the binding agents within each spot are not randomly distributed, but are immobilized in a pattern, e.g., a series of parallel lines, that produces a diffraction pattern when illuminated with a light.
- the binding agents may be immobilized, for example, in eight distinct locations or assay spots on the surface of a device. When a flowing stream of sample is introduced into the device, target molecules bind to the assay spots, resulting in an increased diffraction signal.
- the intensity of the diffraction signal may be used to generate real-time binding curves.
- the illumination and detection beams never pass through the sample, which is particularly advantageous for the detection of analytes (e.g., proteins) in complex biological samples.
- the device used in a diffraction-based assay may be, e.g., a flow-through sensor.
- the patterns on the surface of the device may be created through, e.g.. microlithography, microcontact printing, inkjet writing, robotic spotting, dip pen nanolithography, nanolithograpahy by atomic force microscopy, or near-field optical scanning lithography.
- the device may be made of any suitable material, e.g., a synthetic polymer (e.g., polystyrene), glass, metal, silicon, or semiconductor.
- the device employed may be disposable.
- the invention enables the direct study of multiple biomolecular interactions in parallel including, e.g., protein-protein interactions, nucleic acid interactions, and nucleic acid-protein interactions.
- the surface of the sensor may be coated with different immobilized binding agents known in the art. Immobilized avidin groups on the surface of the sensor may be used for high-affinity immobilization of biotinylated binding agents, e.g., biotinylated antibodies or biotinylated polynucleotides. Protein G on the surface of the sensor may bind to the Fc region of immunoglobulin molecules, allowing oriented immobilization of antibodies as binding agents on the surface of the device. Goat Anti-Mouse-Fc (GAM-Fc)-coated surfaces bind to the Fc region of mouse antibodies, allowing oriented immobilization of binding agents, e.g., mouse antibodies, on the surface of the device employed by the invention.
- Immobilized avidin groups on the surface of the sensor may be used for high-affinity immobilization of biotinylated binding agents, e.g., biotinylated antibodies or biotinylated polynucleotides.
- Immobilized carboxylate groups on an amine-reactive surface may be used to covalently link binding agents, e.g., with amide bonds, to the device's surface via an amine coupling reaction.
- Proteins, peptides, nucleic acids, and other biomolecules can be immobilized.
- Other exemplary reactive linking groups e.g., hydrazines, hydroxylamines, thiols, carboxylic acids, epoxides, trialkoxysilanes, dialkoxysilanes, and chlorosilanes may be attached to the surface of the device, such that binding agents may form chemical bonds with those linking groups to immobilize them on the surface of the device.
- a variety of detection methods may be used with the methods of the invention to detect or measure the concentration of an analyte.
- Surface-enhanced Raman spectroscopy (SERS) or infrared (IR) spectroscopy may be used.
- Other optical techniques that may be applied to the methods of the invention are fluorescence or phosphorescence.
- Non-optical techniques e.g., voltametric or amperometric methods, may also be used.
- SPRS Surface plasmon resonance spectroscopy
- FTR frustrated total reflection
- evanescent wave ellipsometry scattered total internal reflection
- optical wave guide sensors evanescent wave based imaging, e.g., critical angle resolved imaging, luminescence, and absorbance are other methods that may be used for the detection of analytes in the methods of the invention described herein.
- the methods of the invention may be used for the quantitative measurement of analytes across a broad dynamic range, from femtomolar to millimolar concentrations.
- the methods of the invention permit a wide range of applications including, e.g., aggregation studies, substrate-activity measurements, enzyme inhibition studies, monitoring levels of biomarkers (with and without disease relevance), and the detection of large species such as viral particles, microorganisms, and cells.
- the methods described herein may be used to diagnose a disease (e.g., cancer, an autoimmune disease, diabetes, or an infection) in a subject.
- a disease e.g., cancer, an autoimmune disease, diabetes, or an infection
- the methods of the invention may be used to diagnose a disease in a subject that results in the expression or production of a particular analyte.
- a diagnosis may be made if, for example, the presence of the analyte is detected in a biological sample obtained from the subject.
- the disease being diagnosed may be cancer (e.g., a carcinoma, lymphoma, blastoma, sarcoma, or leukemia). More particular examples of such cancers include, e.g., prostate cancer, squamous cell cancer, small-cell lung cancer, non-small-cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, vulval cancer, thyroid cancer, hepatic carcinoma, gastric cancer, melanoma, and various types of head and neck cancer.
- cancers e.g., a carcinoma, lymphoma, blastoma, sarcoma, or leukemia.
- the disease may be, e.g., an autoimmune disease.
- the autoimmune disease being diagnosed may be, e.g., autoimmune hepatitis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, type I diabetes, rheumatoid arthritis, psoriasis, Hashimoto's thyroiditis, Graves' disease, Sjogren's syndrome, or scleroderma.
- infections e.g., bacterial or viral infections
- exemplary bacteria and viruses that may lead to an infection include hepatitis C, human immunodeficiency virus (HIV), adenovirus type 2 hexon, Aspergillus fumigatus, Borrelia afzelii, Borrelia garninii, Campylobacter jejuni, Candida albicans, Chlamydia, coxsackievirus B l , coxsackievirus B5. coxsackievirus B6, cytomegalovirus, Echinococcus.
- HIV human immunodeficiency virus
- adenovirus type 2 hexon Aspergillus fumigatus
- Borrelia afzelii Borrelia garninii
- Campylobacter jejuni Candida albicans
- Chlamydia coxsackievirus B l
- Physicians and researchers may use the methods of the invention described herein to detect plasma biomarkers, e.g., lipoproteins or cardiac biomarkers or monitor thyroid function. Additionally, physicians and researchers may use the methods of the invention to detect hormones to assess various physical conditions, such as pregnancy, ovulation, menopause, and diseases such as cancer. Physicians and researchers may also use the invention to detect various cytokines, which are initially detected at picomolar levels, and other biomarkers (e.g., CRP).
- CRP biomarkers
- the methods of the invention speed the detection of an analyte in a number of ways including, e.g., quantifying analyte concentration and purity, characterizing binding kinetics, determining specificity and cross-reactivity, optimizing analyte concentrations, step times, buffers, and additive composition, monitoring assay performance and matrix effects, and multiplexing analytes with minimized interference.
- a dotLabTM avidin-functionalized optical diffraction device (Axela Inc., Canada) was used to detect a cardiac biomarker, the N-terminal portion of proBNP (brain natriuretic peptide) (NTproBNP).
- the exemplary experiments involved pre- mixing all assay reagents to prepare a complex or "sandwich" (Table 1). The antibody concentrations outlined in Table 1 were mixed with 0 pg/ml, 0.1 pg/ml, 1 pg/ml, and 10 pg/ml of NTproBNP in vials and incubated overnight at 4°C. Different avidin-functionalized optical diffraction devices were then contacted with the sandwiches. The dinitophenyl (DNP) amplification reagent was subsequently added to the sensor, followed by anti-DNP-HRP antibody. Finally, TMB was added to the sensor. Detailed assay conditions are listed in Table 2. Table 1
- the tyramide signal amplification (TSA) kit was purchased from Perkin Elmer (Cat. No. NEL747B) and included a concentrated DNP amplification reagent, DNP amplification diluents, and anti-DNP-HRP antibody that was diluted in BSA- Tween-20 (BSA-T).
- BSA-T BSA- Tween-20
- the concentrated DNP amplification reagent was diluted in 150 ⁇ l of dimethyl sulfoxide (DMSO) and stored as a stock solution. The working solution was diluted 1 :50 in the DNP amplification diluents just prior to the assay and discarded after use.
- DMSO dimethyl sulfoxide
- the anti-DNP- HRP antibody was diluted 1 : 100 in 5 mg/ml BSA in PBS supplemented with 0.025% Tween-20 (PBS-T) and stored at 4°C until use.
- TrueBlue TMB was used as the precipitating substrate.
- the buffer system was PBS supplemented with 0.025% Tween-20 and the blocking reagent was 5 mg/ml BSA in PBS supplemented with 0.025% Tween-20.
- the TMB signal reached the limit of the detector within 100 seconds, and at 1 pg/ml of NTproBNP, the TMB signal reached the limit of the detector in 700 seconds.
- a 5 pg/ml sample of NTproBNP in the sandwich resulted in 0.04 diffraction intensity (DI) signal in the first 100 seconds.
- DI diffraction intensity
- FIGs 1 and 2 illustrate the enhanced sensitivity of detection using both TSA and TMB. Note that the TMB signal in Figure 1 was normalized to aid comparison. Figure 2 shows representative traces of the experiments performed to demonstrate the added sensitivity of using TSA combined with precipitating TMB.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des procédés, des compositions, et des trousses pour détecter un analyte à de basses concentrations dans un échantillon par diffraction optique et un procédé d'amplification de signal en deux étapes. Les procédés de l'invention peuvent être utilisés pour déterminer la présence de divers biomarqueurs dans un échantillon provenant d'un sujet et faciliter le diagnostic d'une maladie et ses évaluations cliniques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92520707P | 2007-04-19 | 2007-04-19 | |
US60/925,207 | 2007-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008128352A1 true WO2008128352A1 (fr) | 2008-10-30 |
Family
ID=39875031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2008/000750 WO2008128352A1 (fr) | 2007-04-19 | 2008-04-21 | Procédés et compositions pour amplifier un signal |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008128352A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103336115A (zh) * | 2013-07-17 | 2013-10-02 | 江阴泽成生物技术有限公司 | 一种人甲状腺过氧化物酶抗体(TPOAb)的磁微粒化学发光免疫分析试剂盒及其检测方法 |
WO2013148498A1 (fr) * | 2012-03-27 | 2013-10-03 | Ventana Medical Systems, Inc. | Conjugués de signalisation, et procédés d'utilisation |
JP2015135338A (ja) * | 2008-10-31 | 2015-07-27 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン |
WO2016061460A1 (fr) * | 2014-10-17 | 2016-04-21 | Carnegie Mellon University | Dosages améliorés pour la détection de biomolécules basés sur l'amplification du signal par tyramide et des sondes de gamma-pna |
WO2018148461A1 (fr) * | 2017-02-09 | 2018-08-16 | Essenlix Corp. | Dosage avec amplification |
US10778913B2 (en) | 2013-03-12 | 2020-09-15 | Ventana Medical Systems, Inc. | Digitally enhanced microscopy for multiplexed histology |
CN113195731A (zh) * | 2018-12-17 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 灵敏的葡萄糖测定法 |
CN114235781A (zh) * | 2021-12-22 | 2022-03-25 | 上海海洋大学 | 基于表面增强拉曼光谱技术定量检测海水中β-半乳糖苷酶的方法 |
US11567008B2 (en) | 2018-10-31 | 2023-01-31 | Sony Corporation | Immunostaining method, immunostaining system, and immunostaining kit |
US11712177B2 (en) | 2019-08-12 | 2023-08-01 | Essenlix Corporation | Assay with textured surface |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196306A (en) * | 1989-03-29 | 1993-03-23 | E. I. Du Pont De Nemours And Company | Method for the detection or quantitation of an analyte using an analyte dependent enzyme activation system |
US6828109B2 (en) * | 2000-12-15 | 2004-12-07 | James R. Bell, Jr. | Methods for detecting an analyte of interest using catalyzed reporter deposition of tyramide |
US7008794B2 (en) * | 2000-03-22 | 2006-03-07 | Axela Biosensors Inc. | Method and apparatus for assay for multiple analytes |
WO2008036802A2 (fr) * | 2006-09-21 | 2008-03-27 | Prometheus Laboratories Inc. | Puces a anticorps permettant de detecter des transducteurs de signal multiples dans des cellules circulantes rares |
-
2008
- 2008-04-21 WO PCT/CA2008/000750 patent/WO2008128352A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196306A (en) * | 1989-03-29 | 1993-03-23 | E. I. Du Pont De Nemours And Company | Method for the detection or quantitation of an analyte using an analyte dependent enzyme activation system |
US7008794B2 (en) * | 2000-03-22 | 2006-03-07 | Axela Biosensors Inc. | Method and apparatus for assay for multiple analytes |
US6828109B2 (en) * | 2000-12-15 | 2004-12-07 | James R. Bell, Jr. | Methods for detecting an analyte of interest using catalyzed reporter deposition of tyramide |
WO2008036802A2 (fr) * | 2006-09-21 | 2008-03-27 | Prometheus Laboratories Inc. | Puces a anticorps permettant de detecter des transducteurs de signal multiples dans des cellules circulantes rares |
Non-Patent Citations (1)
Title |
---|
BOBROW M.N. ET AL.: "Catalyzed reporter deposition, a novel method of signal amplification", J. IMMUNOL. METHODS, vol. 125, 1989, pages 279 - 285, XP002045235 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015135338A (ja) * | 2008-10-31 | 2015-07-27 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン |
US10557851B2 (en) | 2012-03-27 | 2020-02-11 | Ventana Medical Systems, Inc. | Signaling conjugates and methods of use |
WO2013148498A1 (fr) * | 2012-03-27 | 2013-10-03 | Ventana Medical Systems, Inc. | Conjugués de signalisation, et procédés d'utilisation |
JP2015514214A (ja) * | 2012-03-27 | 2015-05-18 | ヴェンタナ メディカル システムズ, インク. | シグナリングコンジュゲート及び使用法 |
US11906523B2 (en) | 2012-03-27 | 2024-02-20 | Ventana Medical Systems, Inc. | Signaling conjugates and methods of use |
AU2013240090B2 (en) * | 2012-03-27 | 2017-01-05 | Ventana Medical Systems, Inc. | Signaling conjugates and methods of use |
US10041950B2 (en) | 2012-03-27 | 2018-08-07 | Ventana Medical Systems, Inc. | Signaling conjugates and methods of use |
US11070750B2 (en) | 2013-03-12 | 2021-07-20 | Ventana Medical Systems, Inc. | Digitally enhanced microscopy for multiplexed histology |
US10778913B2 (en) | 2013-03-12 | 2020-09-15 | Ventana Medical Systems, Inc. | Digitally enhanced microscopy for multiplexed histology |
US12126880B2 (en) | 2013-03-12 | 2024-10-22 | Ventana Medical Systems, Inc. | Digitally enhanced microscopy for multiplexed histology |
CN103336115A (zh) * | 2013-07-17 | 2013-10-02 | 江阴泽成生物技术有限公司 | 一种人甲状腺过氧化物酶抗体(TPOAb)的磁微粒化学发光免疫分析试剂盒及其检测方法 |
US11124822B2 (en) | 2014-10-17 | 2021-09-21 | Carnegie Mellon University | Enhanced biomolecule detection assays based on tyramide signal amplification and gammaPNA probes |
WO2016061460A1 (fr) * | 2014-10-17 | 2016-04-21 | Carnegie Mellon University | Dosages améliorés pour la détection de biomolécules basés sur l'amplification du signal par tyramide et des sondes de gamma-pna |
WO2018148461A1 (fr) * | 2017-02-09 | 2018-08-16 | Essenlix Corp. | Dosage avec amplification |
US11940382B2 (en) | 2017-02-09 | 2024-03-26 | Essenlix Corporation | Assay with amplification |
US11567008B2 (en) | 2018-10-31 | 2023-01-31 | Sony Corporation | Immunostaining method, immunostaining system, and immunostaining kit |
CN113195731A (zh) * | 2018-12-17 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 灵敏的葡萄糖测定法 |
US20220145353A1 (en) * | 2018-12-17 | 2022-05-12 | Hoffmann-La Roche Inc. | Sensitive glucose assay |
US11712177B2 (en) | 2019-08-12 | 2023-08-01 | Essenlix Corporation | Assay with textured surface |
CN114235781A (zh) * | 2021-12-22 | 2022-03-25 | 上海海洋大学 | 基于表面增强拉曼光谱技术定量检测海水中β-半乳糖苷酶的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008128352A1 (fr) | Procédés et compositions pour amplifier un signal | |
Fathil et al. | Diagnostics on acute myocardial infarction: Cardiac troponin biomarkers | |
Chandra et al. | Protein microarrays and novel detection platforms | |
Luppa et al. | Immunosensors—principles and applications to clinical chemistry | |
CN100420947C (zh) | 用单一捕获剂定量检测特异性分析物的方法及其试剂盒 | |
Zeidan et al. | Nano-SPRi aptasensor for the detection of progesterone in buffer | |
WO2008016680A1 (fr) | Procédés et systèmes destinés à détecter et/ou à trier des cibles | |
US20090117670A1 (en) | Detection of target molecules in a sample by using a magnetic field | |
CN104245960B (zh) | 用于生物测定的信号放大的方法和系统 | |
Bocková et al. | Surface plasmon resonance biosensor for detection of pregnancy associated plasma protein A2 in clinical samples | |
Guo et al. | Immunoassays on thiol-ene synthetic paper generate a superior fluorescence signal | |
US9341621B2 (en) | Ultrasensitive detection of biomolecules using immunoseparation and diffractometry | |
Lee et al. | Quenching effect on gold nano-patterned cardiac troponin I chip by total internal reflection fluorescence microscopy | |
Gong et al. | A facile strategy for multiplex protein detection by a fluorescent microsphere-based digital immunoassay | |
Qi et al. | Phage M13KO7 detection with biosensor based on imaging ellipsometry and AFM microscopic confirmation | |
CN109781972B (zh) | 一种免疫定量检测方法和应用 | |
US8158342B2 (en) | Method for the identification of human immunodeficiency virus related antibodies in blood | |
US20090280575A1 (en) | Method for quantitative measurement of thyroid hormones and related antibodies in a serum sample | |
US9285362B2 (en) | Measuring multiple analytes over a broad range of concentrations using optical diffraction | |
Latterich et al. | Label-free detection of biomolecular interactions in real time with a nano-porous silicon-based detection method | |
KR100511055B1 (ko) | 효소침전반응과 결합된 spr을 이용한 바이오칩 및바이오센서 측정방법 | |
Lee et al. | Quantitative analysis of human serum leptin using a nanoarray protein chip based on single-molecule sandwich immunoassay | |
US20120258882A1 (en) | Method for quantitatively detecting biomolecules | |
Karoń et al. | A versatile approach to quality control of protein-based receptor layers by reversible, nonspecific staining for multiplex SPRi immunosensing | |
US20100021930A1 (en) | Application of surface plasmon resonance technology to maternal serum screening for congenital birth defects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08748164 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08748164 Country of ref document: EP Kind code of ref document: A1 |